Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases

A compound represented by formula (1):

• enantiomers, diastereomers and tautomers thereof and pharmaceutically acceptable salts thereof,
• wherein:
• one of Q1 to Q5 is a nitrogen atom and the remaining radicals are carbon atoms;
• R1 is selected from the group consisting of H, C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl, C0-6 alkylene-C3-10 cycloalkyl, C0-6 alkylene-C3-10 heterocycloalkyl, and C0-6 alkylene-5-membered heteroaromatic ring system containing 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O and S,
• wherein alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl and the 5-membered heteroaromatic ring system are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of OH, oxo, CN, O—C1-6 alkyl, O-halo-C1-6 alkyl, C1-6 alkyl, halo-C1-6 alkyl, halogen, COOR10, CON(R10)2, SO2R10, SO2N(R10)2, NR10COR10, NR10SO2R10 and N(R10)2;
• R2 is selected from the group consisting of H, C1-6 alkyl and halo-C1-6 alkyl,
• or R1 and R2 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing an additional heteroatom selected from O, S, SO, SO2 or NR10, wherein the ring is unsubstituted or substituted with one to four substitutents independently selected from halogen, oxo or C1-6-alkyl;
• R3 is H, C1-6 alkyl, halo-C1-6 alkyl, CN or halogen,
• wherein alkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of O—C1-6 alkyl, O-halo-C1-6 alkyl, oxo and OH;
• R4 is SO2—(CR8R8)yR7 or (CR8R8)x—R11;
• R5 is pyridinone, a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S,
• wherein pyridinone, aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from halogen, CN, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, halo-C1-6 alkyl, OH, O—C1-6 alkyl, O-halo-C1-6 alkyl, C3-10 cycloalkyl, O—C3-10 cycloalkyl, COOR9, C(O)R9, C(O)N(R9)2, SO2—N(R9)2, SO2—R9, C3-10 heterocycloalkyl, phenyl, or 5-6 membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S,
• wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, phenyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, ═N—OH, ═N—O—(C1-6 alkyl), N(R9)2, O—C1-6 alkyl, COOH, CON(R9)2, CN, NR9—COR10, C3-10 cycloalkyl, C3-10 heterocycloalkyl, and 6-10 membered mono- or bicyclic aryl, or wherein two adjacent substituents may complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S, SO, SO2 or NR10, wherein the ring is unsubstituted or substituted with one to four substituents independently selected from halogen, oxo, ═N—OH, ═N—O—(C1-6 alkyl), OH, O—C1-6-alkyl, O-halo-C1-6-alkyl, C1-6-alkyl, C3-6-cycloalkyl or halo-C1-6-alkyl;
• R6 is H, C1-6 alkyl, halo-C1-6 alkyl or halogen;
• R7 is C1-10 alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, 6-10 membered mono- or bicyclic aryl or
• 5-10 membered mono- or bicyclic heteroaryl,
• wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, O—C1-6 alkyl, O-halo-C1-6 alkyl, C1-6 alkyl, halo-C1-6 alkyl and NH2,
• and wherein alkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, O—C1-6 alkyl, O-halo-C1-6 alkyl and NH2;
• R8 is independently H, C1-4 alkyl, O—C1-4 alkyl, halo-C1-4 alkyl or halogen;
• R9 is independently selected from H, C1-6 alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, phenyl,
• 5-6 membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O or S,
• wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, O-C1-6 alkyl, O-halo-C1-6 alkyl, phenyl, heteroaryl, halogen, NH2, NH(C1-6 alkyl), N(C1-6 alkyl)2, C3-10 heterocycloalkyl and C3-10 cycloalkyl,
• wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C1-6 alkyl, halo-C1-6 alkyl, OH, O—C1-6 alkyl, O-halo-C1-6 alkyl, phenyl, heteroaryl, halogen, NH2, NH(C1-6 alkyl), N(C1-6 alkyl)2 and C3-10 cycloalkyl,
• and wherein phenyl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, O—C1-6 alkyl, O-halo-C1-6 alkyl, halogen, C1-6 alkyl, halo-C1-6 alkyl, NH2, NH(C1-6 alkyl), N(C1-6 alkyl)2 and C3-10 cycloalkyl;
• R10 is independently selected from H, C1-6 alkyl, halo-C1-6 alkyl or C3-10 cycloalkyl;
• R11 is C2-10 alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, 6-10 membered mono- or bicyclic aryl or 5-10 membered mono- or bicyclic heteroaryl,
• wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O—C1-6 alkyl, O-halo-C1-6 alkyl, C1-6 alkyl, halo-C1-6 alkyl and NH2;
• x is 1, 2 or 3;
• and
• y is 0, 1, or 2;
• with the proviso that for R5 the 5-14 membered mono-, bi- or tricyclic heteroaryl containing ring is not
• and with the proviso that (CR8R8)x—R11 is not